News

Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
A Cambridge biomedical research institute that launched last year with a roughly $600 million venture capital investment has ...
Sarepta Therapeutics obtained traditional FDA approval for ambulatory DMD patients and accelerated approval for ...
The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...
Certain Sarepta Therapeutics Inc. insiders were accused in a stockholder lawsuit of reaping a combined $6.2 million selling ...
Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.
Following recent FDA-related challenges and cost-cutting initiatives, Sarepta has secured an extension on a large chunk of ...
The debt refinancing follows the firm's recent trouble with the FDA and efforts to refocus its pipeline priorities, preserve resources, and meet financial obligations.
What To Know: Under privately negotiated exchange agreements, Sarepta will swap about $700 million in aggregate principal amount of its existing convertible notes for approximately $602 million in new ...
Morning. Today, we see fallout from the FDA’s rejection of Replimune’s melanoma drug affecting another biotech, learn how ...
Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...